Standout Papers

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma 2011 2026 2016 2021 2.6k
  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014)
    Stephen M. Ansell, Alexander M. Lesokhin et al. New England Journal of Medicine
  2. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease (2011)
    John Koreth, Ken‐ichi Matsuoka et al. New England Journal of Medicine
  3. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma (2017)
    Robert Chen, Pier Luigi Zinzani et al. Journal of Clinical Oncology
  4. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation (2014)
    Philippe Armand, Haesook T. Kim et al. Blood
  5. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome (2016)
    Margaretha G.M. Roemer, Ranjana H. Advani et al. Journal of Clinical Oncology
  6. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure (2016)
    Philippe Armand, Margaret A. Shipp et al. Journal of Clinical Oncology
  7. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018)
    Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology
  8. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma (2017)
    Lakshmi Nayak, Fábio M. Iwamoto et al. Blood
  9. Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation (2014)
    Timothy J. Henrich, Emily Hanhauser et al. Annals of Internal Medicine

Immediate Impact

26 by Nobel laureates 18 from Science/Nature 76 standout
Sub-graph 1 of 21

Citing Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
2 intermediate papers

Works of Philippe Armand being referenced

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
2016 Standout
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
2016
and 4 more

Author Peers

Author Last Decade Papers Cites
Philippe Armand 8601 5734 4903 6279 332 17.1k
Norbert Schmitz 8211 9843 5692 3851 394 16.8k
David C. Linch 6847 6519 8831 3691 355 20.5k
Oliver W. Press 7534 6788 1617 3337 384 17.5k
Gianluca Gaïdano 9322 10840 2802 4488 610 20.0k
John G. Gribben 8204 8634 4954 10736 471 23.5k
Wyndham H. Wilson 8771 7941 1184 4773 324 17.2k
Anton Hagenbeek 7618 11213 2669 2367 257 16.0k
Ranjana H. Advani 9864 12994 1708 4473 450 19.3k
Kensei Tobinai 5704 7148 1215 4853 422 13.3k
H. Miles Prince 5695 4093 4056 3102 416 14.4k

All Works

Loading papers...

Rankless by CCL
2026